Just caught Relay Therapeutics (RLAY) jumping 19% today and hitting a new 52-week high at $10.98. What's interesting here isn't just the stock pop—it's what's actually happening under the hood with their pipeline.

The company just reported 2025 results and honestly, the trajectory looks pretty solid for a clinical-stage biotech. Q4 losses narrowed to $54.9M per share versus $76M a year ago. Full year loss came in at $276.5M, down from $337.7M in 2024. More importantly, they're actually generating revenue now—$15.4M for the year, up from $10M, thanks to their Elevar Therapeutics licensing deal.

But here's where it gets interesting if you're watching the biotech space. Their lead program Zovegalisib (RLY-2608) is in Phase 3 for HR+/HER2- metastatic breast cancer, and they're expecting triplet combination data plus frontline Phase 3 plans in 2026. There's also a Phase 1/2 trial running for vascular anomalies with initial readouts coming in H1 2026. This is the kind of near-term catalyst setup that gets investors excited—multiple shots on goal.

Beyond that, they've got RLY-8161 (NRAS inhibitor) in preclinical work and a Fabry disease program in early stages. The out-licensed Lirafugratinib program to Elevar keeps generating milestone payments flowing back to Relay, which is smart capital management.

What caught my attention is the cash position—$554.5M in cash and investments, which management says funds them through 2029. That's a meaningful runway for a company trying to jump to the next level of clinical validation. The stock had been trading between $1.77 and $10.98 over the past year, so today's move to touch that upper range makes sense given the 2026 readout calendar.

CEO Sanjiv Patel called 2026 "pivotal," and I'd agree—multiple clinical readouts across cancer and rare disease programs could position them for commercialization conversations if the data holds up. It's exactly the kind of inflection point that biotech investors are hunting for right now. Worth keeping on the radar if you're tracking precision medicine plays.